Study of pathophysiology and new treatment approach in Langerhans cell histiocytosis
Project/Area Number |
25860894
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Pediatrics
|
Research Institution | University of Occupational and Environmental Health, Japan |
Principal Investigator |
HONDA Yuko 産業医科大学, 医学部, 助教 (10566409)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
|
Keywords | ランゲルハンス細胞組織球症 / 骨病変 / RANKL / RANK / 小児 / LCH / 骨融解 |
Outline of Final Research Achievements |
The expression of the receptor activator of NF-kappaB ligand (RANKL)/ RANK/osteoprotegerin (OPG) system plays an important role in osteolytic lesion cases in patients who have a Langerhans cell histiocytosis. Here, we evaluated the gene mutations related to the congenital bone disease in children with LCH. In the result, we didn’t find any mutations in these patients who had entered remission, however the number of patients were small, so further investigation is needed.
|
Report
(4 results)
Research Products
(4 results)